ArticleThe Lancet regional health. Western Pacific2026
Benchmarking progress in cause-specific cancers in China: a nationwide analysis of premature mortality from 1990 to 2023.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The United Nations passed Sustainable Development Goal 3.4 (SDG 3.4), which aims to reduce by one-third premature mortality from noncommunicable diseases, including cancer, by 2030. However, there is still no comprehensive assessment of the historical trends and projections in premature cancer mortality nationally, regionally, and by cancer type. Methods: We estimated premature mortality by sex, age, and 33 provinces for China using the results of the Global Burden of Disease Study 2023. The premature mortality from total cancers and 29 cancer types was estimated for ages 30-69 years, using standard life table methods. The average annual rate of change was calculated to examine the past trends in premature mortality from 1990 to 2023. We further assessed whether historical trends would be sufficient to meet the SDG 3.4 targets for reducing premature mortality by 2030. Findings: Over the period from 1990 to 2023, the cancer-related premature mortality declined from 13.11% to 6.66% (AAPC = -1.93%, 95% CI = -2.20% to -1.66%). In particular, stomach cancer (AAPC = -3.80%, 95% CI = -4.18% to -3.42%), esophageal cancer (AAPC = -3.40%, 95% CI = -3.75% to -3.06%), nasopharynx cancer (AAPC = -3.55%, 95% CI = -4.03% to -3.07%), and Hodgkin's lymphoma (AAPC = -4.89%, 95% CI = -5.12% to -4.66%) showed higher rates of decline. However, increasing premature mortality from pancreatic, breast, and kidney cancers was documented among males in northern, northeastern, and northwestern China. The causes of greatest premature mortality were lung cancer (1.97%), stomach cancer (0.98%), colon and rectum cancer (0.65%), esophageal cancer (0.65%), and liver cancer (0.48%) throughout the study period. In 2023, cancer-related premature mortality peaked in Heilongjiang (11.44%), followed by Chongqing (11.15%), Sichuan (10.49%), Liaoning (10.26%), and Shandong (10.00%) for males. Heilongjiang (6.63%), Jilin (5.63%), Liaoning (5.44%), Xinjiang (5.37%), and Inner Mongolia (4.98%) comprised the five provinces with the highest premature cancer mortality among females. Whereas cancer-related premature mortality declined at an average annual rate of 2.05% from 1990 to 2023, meeting the SDG 3.4 targets necessitates a future decline, 1.3 times faster. Hubei (2.89%), Shanghai (2.75%), and Hong Kong (2.71%) exhibited the fastest decline rates and were projected to meet the SDG 3.4 targets based on current trends. Interpretation: From 1990 to 2023, the probability of dying from cancers declined across all provinces in China. Cancers with primary prevention or early detection strategies in place, such as stomach cancer, colorectal cancer, and cervical cancer, were performing better in premature mortality compared with cancers that lack such strategies, such as kidney cancer, multiple myeloma and pancreatic cancer. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.